Syndax Pharmaceuticals Inc financial data

Symbol
SNDX on Nasdaq
Industry
Pharmaceutical Preparations
Location
35 Gatehouse Drive, Building D, Floor 3, Waltham, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.02K % -36.4%
Debt-to-equity 10 % +33.9%
Return On Equity -53.3 % -39.4%
Return On Assets -48.5 % -36.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 85M shares +23.5%
Common Stock, Shares, Outstanding 85M shares +24.1%
Entity Public Float 1.08B USD +30.1%
Common Stock, Value, Issued 8K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 85.2M shares +22.7%
Weighted Average Number of Shares Outstanding, Diluted 85.2M shares +22.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 185M USD +51.4%
General and Administrative Expense 23M USD +92.5%
Operating Income (Loss) -263M USD -63.7%
Nonoperating Income (Expense) 22.8M USD +200%
Net Income (Loss) Attributable to Parent -241M USD -57%
Earnings Per Share, Basic -3.24 USD/shares -33.9%
Earnings Per Share, Diluted -3.24 USD/shares -33.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 115M USD +99.3%
Other Assets, Current 6.07M USD
Assets, Current 454M USD +2.81%
Property, Plant and Equipment, Net 5K USD -70.6%
Operating Lease, Right-of-Use Asset 1.24M USD +33.8%
Other Assets, Noncurrent 248K USD -64.2%
Assets 543M USD +18.1%
Accounts Payable, Current 8.81M USD +9.33%
Employee-related Liabilities, Current 4.57M USD +49.6%
Liabilities, Current 50.8M USD +114%
Operating Lease, Liability, Noncurrent 327K USD -44.4%
Liabilities 51.1M USD +110%
Retained Earnings (Accumulated Deficit) -975M USD -32.8%
Stockholders' Equity Attributable to Parent 492M USD +12.9%
Liabilities and Equity 543M USD +18.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -83.5M USD -113%
Net Cash Provided by (Used in) Financing Activities 2.17M USD -12.4%
Net Cash Provided by (Used in) Investing Activities -99.4M USD -599%
Common Stock, Shares Authorized 200M shares +100%
Common Stock, Shares, Issued 85M shares +24.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -181M USD -974%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 206M USD +54.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 206M USD +54.8%
Operating Lease, Liability 1.61M USD +41.1%
Depreciation 12M USD -63.6%
Payments to Acquire Property, Plant, and Equipment 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -241M USD -57.6%
Lessee, Operating Lease, Liability, to be Paid 1.8M USD +33.4%
Property, Plant and Equipment, Gross 419K USD 0%
Operating Lease, Liability, Current 1.04M USD +130%
Lessee, Operating Lease, Liability, to be Paid, Year Two 606K USD +3.59%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.2M USD +111%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 189K USD -9.14%
Deferred Tax Assets, Operating Loss Carryforwards 32.7M USD +38.1%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 143K USD 0%
Operating Lease, Payments 924K USD +63%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 33.6M USD +79%
Interest Expense 223K USD -91.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%